Literature DB >> 1529272

Pituitary adenylate cyclase-activating polypeptide relaxes rat gastrointestinal smooth muscle.

Z Mungan1, A Arimura, A Ertan, W J Rossowski, D H Coy.   

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a new member of the secretin/glucagon peptides family, being most homologous to vasoactive intestinal peptide (VIP). The present study was designed to investigate a possible effect of PACAP on the rat gastrointestinal smooth muscle in vitro. We demonstrated that 1) PACAP reduced basal smooth-muscle contractions in all portions of the gastrointestinal tract, but the effect of VIP was region-specific. The inhibitory effect of PACAP in midcolon was approximately 100 times greater than that of VIP. 2) PACAP significantly inhibited smooth-muscle contractions induced by acetylcholine or carbachol. The inhibitory effect of PACAP was not affected by hexamethonium and was additive to the inhibitory effect of atropine and pirenzepine. 3) PACAP inhibited smooth-muscle contractions induced by substance P, cholecystokinin, and galanin, even after atropine treatment. Although the exact mechanism of the inhibitory action of PACAP remains to be clarified, PACAP appears to exert its effect in the rat at a site other than muscarinic receptors, probably through a direct effect on gastrointestinal smooth muscle in vitro.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1529272     DOI: 10.3109/00365529209000091

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Central effects of pituitary adenylate cyclase activating polypeptide (PACAP) on gastric motility and emptying in rats.

Authors:  M Ozawa; M Aono; M Moriga
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

2.  Changes in pituitary adenylate cyclase-activating Peptide 27-like immunoreactive nervous structures in the porcine descending colon during selected pathological processes.

Authors:  Sławomir Gonkowski; Jarosław Całka
Journal:  J Mol Neurosci       Date:  2012-06-17       Impact factor: 3.444

3.  Pituitary adenylate cyclase-activating peptide-immunoreactive nerve fibers in the cat eye.

Authors:  T Elsås; R Uddman; F Sundler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-09       Impact factor: 3.117

4.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor.

Authors:  J R Pisegna; S A Wank
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Distribution and effects of pituitary adenylate cyclase activating peptide in cat and human lower oesophageal sphincter.

Authors:  L Ny; B Larsson; P Alm; P Ekström; J Fahrenkrug; J Hannibal; K E Andersson
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

6.  Nitric oxide synthase-containing, peptide-containing, and acetylcholinesterase-positive nerves in the cat lower oesophagus.

Authors:  L Ny; P Alm; P Ekström; J Hannibal; B Larsson; K E Andersson
Journal:  Histochem J       Date:  1994-09

7.  Distribution of PACAP (pituitary adenylate cyclase-activating polypeptide)-like and helospectin-like peptides in the teleost gut.

Authors:  C Olsson; S Holmgren
Journal:  Cell Tissue Res       Date:  1994-09       Impact factor: 5.249

8.  Diabetes Affects the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)-Like Immunoreactive Enteric Neurons in the Porcine Digestive Tract.

Authors:  Katarzyna Palus; Michał Bulc; Jarosław Całka; Łukasz Zielonka; Marcin Nowicki
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

9.  The pituitary adenylate cyclase activating polypeptide type 1 receptor (PAC1-R) is expressed on gastric ECL cells: evidence by immunocytochemistry and RT-PCR.

Authors:  N Zeng; T Kang; R M Lyu; H Wong; Y Wen; J H Walsh; G Sachs; J R Pisegna
Journal:  Ann N Y Acad Sci       Date:  1998-12-11       Impact factor: 5.691

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.